<DOC>
	<DOCNO>NCT03019419</DOCNO>
	<brief_summary>To investigate safety efficacy perampanel patient sporadic amyotrophic lateral sclerosis</brief_summary>
	<brief_title>Perampanel Sporadic Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>To evaluate effect peramanel 48 week progression disease subject ALS , measure ALS Functional Rating Scale-Revised ( ALSFRS-R )</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>[ Eligibility Criteria Interim Registration ] Patients able submit write informed consent . If patient duly capable study consent unable sign due aggravation disease condition , write informed consent obtain legally authorize representative sign behalf patient confirm patient ' agreement study participation . Patients male female age 40 year 78 year time obtain informed consent Patients clinically definite ALS , clinically probable ALS , clinically probablelaboratory support ALS specify revise El Escorial Airlie House diagnostic criterion . The sum 3 respiratory item ALSFRSR must total 12 point Patients within 2year elapsed time period disease onset time obtain informed consent Patients visit study site outpatient treatment [ Eligibility Criteria Registration ] Subjects meet follow criterion addition inclusion criterion interim registration The progression score ALSFRSR 12 week observation period must 2 5 Patients initiated newly introduce riluzole therapy start observation period . Or receive dose escalation resume administration riluzole therapy previous titration discontinuation Patients initiate newly introduce edaravone therapy start observation period Patients judge eligible continuation study investigator [ Exclusion Criteria ] Patients underwent tracheostomy . Patients experience noninvasive positive pressure ventilation . Patients whose percentpredicted force vital capacity ( % FVC ) â‰¤80 % . Patients progressive bulbar palsy type . Patients cognitive impairment , severe disease renal , cardiovascular , hematological system . Patients hepatic disease . Patients malignant tumor . Pregnant woman woman possibility become pregnant . Patients participate another clinical study within 12 week start observation period . Patients initiated perampanel therapy past present . Patients judge ineligible study entry investigator .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>sporadic ALS</keyword>
	<keyword>perampanel</keyword>
</DOC>